{"organizations": [], "uuid": "d2c60b607b2e4c4f1d7c288d2b1704f87571cee2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180213.html", "section_title": "Archive News &amp; Video for Tuesday, 13 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-catabasis-reports-edasalonexent-pr/brief-catabasis-reports-edasalonexent-preserved-muscle-function-and-substantially-slowed-duchenne-muscular-dystrophy-disease-progression-idUSFWN1Q30ZK", "country": "US", "domain_rank": 408, "title": "Catabasis Reports Edasalonexent Preserved Muscle Function And Substantially Slowed Duchenne Muscular Dystrophy Disease Progression", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.8, "site_type": "news", "published": "2018-02-13T21:23:00.000+02:00", "replies_count": 0, "uuid": "d2c60b607b2e4c4f1d7c288d2b1704f87571cee2"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-catabasis-reports-edasalonexent-pr/brief-catabasis-reports-edasalonexent-preserved-muscle-function-and-substantially-slowed-duchenne-muscular-dystrophy-disease-progression-idUSFWN1Q30ZK", "ord_in_thread": 0, "title": "Catabasis Reports Edasalonexent Preserved Muscle Function And Substantially Slowed Duchenne Muscular Dystrophy Disease Progression", "locations": [], "entities": {"persons": [{"name": "edasalonexent", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters) - catabasis pharmaceuticals inc", "sentiment": "neutral"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 13 (Reuters) - Catabasis Pharmaceuticals Inc:\n* CATABASIS PHARMACEUTICALS REPORTS EDASALONEXENT PRESERVED MUSCLE FUNCTION AND SUBSTANTIALLY SLOWED DUCHENNE MUSCULAR DYSTROPHY DISEASE PROGRESSION THROUGH MORE THAN ONE YEAR OF TREATMENT\n* CATABASIS - PLANS TO INITIATE SINGLE GLOBAL PHASE 3 TRIAL WITH EDASALONEXENT IN PATIENTS WITH DMD REGARDLESS OF MUTATION TYPE IN FIRST HALF OF 2018\n* CATABASIS PHARMACEUTICALS - ‍EDASALONEXENT CONTINUED TO BE WELL TOLERATED WITH NO SAFETY SIGNALS OBSERVED IN TRIAL​\n* CATABASIS PHARMACEUTICALS INC - TOP-LINE RESULTS IN SINGLE GLOBAL PHASE 3 TRIAL WITH EDASALONEXENT IN PATIENTS EXPECTED IN 2020 Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-13T21:23:00.000+02:00", "crawled": "2018-02-14T12:46:27.000+02:00", "highlightTitle": ""}